A novel bispecific immunotherapy developed by Roche AG to target pancreatic cancer showed promising results combined with radiation therapy in preclinical trials carried out at the University of Colorado.
China’s NMPA approved Shanghai Shengdi Pharmaceutical Co. Ltd.’s adebrelimab (SHR-1316) for first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC) in combination with chemotherapy. The approval in mainland China makes adebrelimab the third domestic PD-L1 monoclonal antibody to make it to the domestic market. Shanghai Shengdi is a subsidiary of Jiangsu Hengrui Medicine Co. Ltd.
Findings published in Nature showing that dual blockage of PD-L1 and CD47 can boost the therapeutic effects of oxaliplatin chemotherapy as well as the FOLFOX regimen – in a CT-26 mice tumor model, anyway – served to highlight CD47, a target that has spurred added efforts of late.
PDX Pharmaceuticals Inc.'s ARAC-02 has been selected to enter the Nanotechnology Characterization Laboratory (NCL)'s Assay Cascade Characterization Program.
Immune checkpoint inhibitor (ICI) treatment reduced levels of estrogen and important heart-protective proteins, researchers reported in the Nov. 2, 2022, online edition of Science Translational Medicine. Hormone therapies could target this endocrine-cardiac-immune pathway and mitigate myocarditis risk without affecting treatment responses.
Normunity Inc. emerged from stealth by unveiling $65 million in series A funding and bold plans to tackle one of the critical issues in immuno-oncology. Normunity is based on the research of scientific founder Lieping Chen, of Yale School of Medicine, an early immuno-oncology pioneer who identified and characterized the gene encoding PD-L1 (then called B7-H1) and shortly afterward reporting additional findings that contributed to its recognition as an important target in cancer immunotherapy.
Shanghai Allygen Biologics Co. Ltd. has synthesized new antibody-drug conjugates (ADC) comprising antibodies targeting programmed cell death 1 ligand 1 (CD274; PD-L1) covalently linked to SN-38 through a linker and reported to be useful for the treatment of cancer.
Gilead Sciences Inc. has disclosed the discovery and structure of the potent, oral small molecule programmed cell death 1 ligand 1 (PD-L1) inhibitor GS-4224 (evixapodlin).
TORONTO – Oncocyte Corp. launched Determaio, an immunotherapy response prediction test it said is “the first to comprehensively assess the tumor microenvironment.” This is important because of how smart cancer cells are in that microenvironment, Oncocyte CEO Ronnie Andrews told BioWorld, commandeering natural tissue repair biology and condensing immunological T cells so they back off attacking cancerous tissue.